Division of Research Spotlight
The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. We seek to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 550-plus staff is working on more than 350 epidemiological and health services research projects.
Being vaccinated against COVID-19 during pregnancy provides protection for the baby through its first several months of life, a Kaiser Permanente analysis finds. Protection was stronger against the delta variant than the more recent omicron variant.
Kaiser Permanente study does not support anecdotal reports that postmenopausal bleeding was common after COVID-19 vaccination.
Elderly Black and Latino people were more likely to get a COVID-19 vaccination after they received an email or letter from their Kaiser Permanente doctor, new research finds.
A large Kaiser Permanente analysis of COVID-19 patients confirms the value of vaccination, finding higher rates of hospitalization and advanced medical care for COVID-19 patients who were unvaccinated, were vaccinated but not boosted, or who had an additional health condition such as obesity or heart disease.
A new study led by Kaiser Permanente researchers provides reassurance about vaccinating infants whose mothers took biologic medications for an autoimmune disorder during pregnancy.
COVID-19 patients in Kaiser Permanente Northern California hospitals during the delta surge of 2021 were less likely to die in the hospital of COVID-19 if they were vaccinated, new research finds.
An analysis of early data on the effectiveness of the Pfizer/BioNTech COVID-19 vaccine in children and teens found that a third shot, or booster, extended protection against emergency department and urgent care visits in 16- and 17-year-olds.
Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.
About 75 children are scheduled to receive their first vaccination against COVID-19 as part of the Pfizer/BioNTech vaccine clinical trial through Kaiser Permanente Northern California.
Kaiser Permanente’s Vaccine Study Center is leading a key part of the national safety surveillance effort for the COVID-19 vaccines, tracking patient data for serious side effects.